NanoVibronix’s ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

Dual-System Agreement Highlights Transition Towards Advanced Bedside Navigation

TYLER, Texas–(BUSINESS WIRE)–NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue Medical division (“ENvue” or “ENvue Medical”).

The systems, which are currently expected to be delivered in the third quarter of 2025, will support bedside placement of nasoenteric feeding tubes in adult patients. ENvue’s electromagnetic technology provides clinicians with real-time visualization of tube direction and position during placement, enhancing bedside navigation while complementing standard institutional protocols.

“Increasingly, hospitals are taking a more strategic approach to investing in enteral access technology,” said Dr. Doron Besser, CEO of NanoVibronix and ENvue Medical. “We are seeing a clear shift away from legacy tools and moves toward more advanced solutions that emphasize safety, workflow integration and long-term value. At NanoVibronix and ENvue, we are proving our ability to deliver meaningfully on all three.

“Looking ahead, we are highly energized by the potential new business in our sales pipeline and expanding market opportunities fueled by upcoming innovations that leverage emerging technologies to better meet clinical needs and market demand.”

The agreement includes terms that support the hospital’s migration strategy and reflects a growing trend among U.S. healthcare institutions seeking to update or consolidate their placement technologies. The agreement’s structure reflects alignment with institutional protocols and operational planning.

The ENvue System is FDA-cleared for adult use and is currently being deployed across intensive care, step-down and medical-surgical units nationwide. This agreement follows recent commercial activity in the southeastern U.S. region and marks ENvue’s first formal system adoption in the northeastern U.S. region.

This announcement follows ENvue’s recently granted U.S. patent for electromagnetic navigation in pediatric feeding – a key milestone in the Company’s broader product development strategy.

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct technology platforms:

• Acoustic-based therapeutic technologies, including PainShield^® and UroShield^®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
• ENvue™ Navigation Platform, developed and operated by ENvue Medical, with offices in Arlington Heights, Illinois, and Tel Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.

NanoVibronix aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of the ENvue System and ENvue Medical’s platforms, anticipated commercial expansion and implementation of the ENvue System and ENvue Medical’s platforms in additional medical institutions and markets, market interest in the Company’s technology, including the ENvue System and ENvue Medical’s platforms, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Contacts

Brett Maas, Managing Principal

Hayden IR, LLC

brett@haydenir.com
(646) 536-7331